These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31445022)

  • 1. Atypical Michaelis-Menten kinetics in cytochrome P450 enzymes: A focus on substrate inhibition.
    Leow JWH; Chan ECY
    Biochem Pharmacol; 2019 Nov; 169():113615. PubMed ID: 31445022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical cytochrome p450 kinetics: implications for drug discovery.
    Tracy TS
    Drugs R D; 2006; 7(6):349-63. PubMed ID: 17073518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme Kinetics of Oxidative Metabolism-Cytochromes P450.
    Korzekwa K
    Methods Mol Biol; 2021; 2342():237-256. PubMed ID: 34272697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology.
    Leow JWH; Tang LWT; Chan ECY
    Adv Pharmacol; 2022; 95():131-176. PubMed ID: 35953154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
    Leow JWH; Verma RK; Lim ABH; Fan H; Chan ECY
    Eur J Pharm Sci; 2021 Sep; 164():105889. PubMed ID: 34044117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions.
    Atkins WM
    Annu Rev Pharmacol Toxicol; 2005; 45():291-310. PubMed ID: 15832445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzyme kinetics of oxidative metabolism: cytochromes P450.
    Korzekwa K
    Methods Mol Biol; 2014; 1113():149-66. PubMed ID: 24523112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme kinetics of cytochrome P450-mediated reactions.
    Shou M; Lin Y; Lu P; Tang C; Mei Q; Cui D; Tang W; Ngui JS; Lin CC; Singh R; Wong BK; Yergey JA; Lin JH; Pearson PG; Baillie TA; Rodrigues AD; Rushmore TH
    Curr Drug Metab; 2001 Mar; 2(1):17-36. PubMed ID: 11465149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fundamentals of Enzyme Kinetics: Michaelis-Menten and Non-Michaelis-Type (Atypical) Enzyme Kinetics.
    Seibert E; Tracy TS
    Methods Mol Biol; 2021; 2342():3-27. PubMed ID: 34272689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
    Houston JB; Kenworthy KE
    Drug Metab Dispos; 2000 Mar; 28(3):246-54. PubMed ID: 10681367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro - in vivo extrapolation of hepatic clearance.
    Palacharla RC; Uthukam V; Manoharan A; Ponnamaneni RK; Padala NP; Boggavarapu RK; Bhyrapuneni G; Ajjala DR; Nirogi R
    Eur J Pharm Sci; 2017 Apr; 101():80-89. PubMed ID: 28179134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling atypical CYP3A4 kinetics: principles and pragmatism.
    Houston JB; Galetin A
    Arch Biochem Biophys; 2005 Jan; 433(2):351-60. PubMed ID: 15581591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research progress of the atypical kinetic profiles of cytochrome P450 enzymes].
    Zeng CW; He F; Xia CH; Xiong YQ
    Yao Xue Xue Bao; 2012 Jun; 47(6):725-9. PubMed ID: 22919718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.
    Yadav J; Paragas E; Korzekwa K; Nagar S
    Pharmacol Ther; 2020 Feb; 206():107449. PubMed ID: 31836452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling kinetic data from in vitro drug metabolism enzyme experiments.
    Tracy TS; Hummel MA
    Drug Metab Rev; 2004 May; 36(2):231-42. PubMed ID: 15237853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterotropic cooperativity in oxidation mediated by cytochrome p450.
    Niwa T; Murayama N; Yamazaki H
    Curr Drug Metab; 2008 Jun; 9(5):453-62. PubMed ID: 18537580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.
    Rendic SP; Peter Guengerich F
    Drug Metab Rev; 2018 Aug; 50(3):256-342. PubMed ID: 30717606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
    Lin Y; Lu P; Tang C; Mei Q; Sandig G; Rodrigues AD; Rushmore TH; Shou M
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):368-74. PubMed ID: 11259318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
    Wang Z; Yong Chan EC
    Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.